Introduction:

Currently, the management of treatments in cystic fibrosis (CF) is mainly focused to control symptoms, which consist of mucus retention and chronic infection. The pulmonary route is proposed as an interesting alternative for administering drugs, especially antimicrobials. However, the rapid clearance of these, which leads to low drug levels and increased dosage regimens, as well as the appearance of adverse effects, make nanotechnology an interesting strategy for this disease.

Objective:

to study and analyze the different nanoparticulate systems available for use via the lung, specifying the use of lipid systems for the treatment of CF.

Method:

a non-systematic search of articles in different databases was carried out, mainly in the last 10 years, following established guidelines for selecting keywords.

Results:

The progress in recent years makes CF become an adult disease. Current treatments are increasingly being displaced by other alternatives, such as nanoparticular systems, being suitable for pulmonary administration due to their small size, sustained release and high biocompatibility. Among these, liposomes stand out for their structural similarity to lung surfactant, as well as for their ability to destroy bacterial biofilms. Most of the formulations contained a single drug.

Conclusion:

Scientific literature evidenced that research studies should be directed towards the development of formulations that are intended to destroy the biofilm.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )